Breaking Finance News

Exane BNP Paribas announced Shire PLC (LON:SHP), upholding its stock price target at 5,900.00GBX today

Just yesterday Shire PLC (LON:SHP) traded -0.97% lower at 5,002.50GBX. Shire PLC’s 50-day moving average is 4,985.30GBX and its 200-day moving average is 4,508.27GBX. The last stock price is up 11.17% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 324,300 shares of SHP traded hands, down from an average trading volume of 1,971,700

In a report released on 9/30/2016 Exane BNP Paribas hold steady the stock price target of Shire PLC (LON:SHP) from 5,900.00GBX to 5,900.00GBX reporting a possible upside of 0.18%.

Previously on 9/29/2016, Goldman Sachs released a statement about Shire PLC (LON:SHP) held steady the target price at 6,300.00GBX. At the time, this indicated a possible upside of 0.23%.

Recent Performance Chart

Shire PLC (LON:SHP)

Shire PLC has 52 week low of 2,707.19GBX and a 52 week high of 5,377.00GBX with a PE ratio of 31.25 and has a market capitalization of 0 GBX.

In addition to Exane BNP Paribas reporting its stock price target, a total of 18 brokerages have issued a ratings update on the company. The average stock price target is 73.73GBX with 6 brokerages rating the stock a strong buy, 16 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Shire PLC (LON:SHP)

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *